Literature DB >> 31113738

Predictive models of mortality and hospital readmission of patients with decompensated liver cirrhosis.

Rui Gaspar1, Susana Rodrigues2, Marco Silva2, Pedro Costa-Moreira2, Rui Morais2, Patricia Andrade2, Helder Cardoso2, Andreia Albuquerque2, Rodrigo Liberal2, Guilherme Macedo2.   

Abstract

INTRODUCTION: Complications of cirrhosis are one the major causes of hospital admission associated with high morbimortality rates and social and economic charges. The aims of this study were to evaluate hospital readmission and mortality rates and predictive factors for hospital readmission and mortality.
METHODS: Patients with decompensated cirrhosis admitted to our institution between 2008-2014 were retrospectively analyzed.
RESULTS: Included 427 admissions from 177 patients with cirrhosis with mean age of 59.0 ± 12.3 years. The major cause was alcoholic-related liver disease and the median duration of admission was 9.0 days (IQR 6.0-14.0). During the follow-up period,there were 250 readmissions from 95 patients, with a median of 58 (IQR27-134) days for readmission, representing 58.5% of the total number of admissions.The 180-day mortality rate was 35.0%. In the multivariate analysis, ascites, smoking and MELD Na were associated with 180-day mortality. Creatinine, albumin, esophageal variceal bleeding, previous variceal banding, lactulose, rifaximin and proton pump inhibitors use were independently associated with need of readmission. Based on regression analysis, two models were calculated to predict 180-day mortality (AUROC 0.74 (0.682-0.794)) and need for readmission(AUROC 0.821 (0.781-0.861)), p < 0.001.
CONCLUSION: The readmission rate and mortality of cirrhotic patients are still very high and it is a priority to determine preventable risk factors to improve patient outcome. Two models were created to predict 180-day mortality(AUROC 0.74) and need for readmission(AUROC 0.821), that could guide the management of the patients at the time of admission.
Copyright © 2019 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  180-day mortality; Chronic liver disease; Hospital readmission; Predictive factors

Mesh:

Year:  2019        PMID: 31113738     DOI: 10.1016/j.dld.2019.03.016

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  3 in total

Review 1.  New dimensions for hospital services and early detection of disease: a Review from the Lancet Commission into liver disease in the UK.

Authors:  Roger Williams; Charles Alessi; Graeme Alexander; Michael Allison; Richard Aspinall; Rachel L Batterham; Neeraj Bhala; Natalie Day; Anil Dhawan; Colin Drummond; James Ferguson; Graham Foster; Ian Gilmore; Raphael Goldacre; Harriet Gordon; Clive Henn; Deirdre Kelly; Alastair MacGilchrist; Roger McCorry; Neil McDougall; Zulfiquar Mirza; Kieran Moriarty; Philip Newsome; Richard Pinder; Stephen Roberts; Harry Rutter; Stephen Ryder; Marianne Samyn; Katherine Severi; Nick Sheron; Douglas Thorburn; Julia Verne; John Williams; Andrew Yeoman
Journal:  Lancet       Date:  2021-03-11       Impact factor: 202.731

2.  Alcohol-Related Liver Disease in the Covid-19 Era: Position Paper of the Italian Society on Alcohol (SIA).

Authors:  Gianni Testino; Teo Vignoli; Valentino Patussi; Pierluigi Allosio; Maria Francesca Amendola; Sarino Aricò; Aniello Baselice; Patrizia Balbinot; Vito Campanile; Tiziana Fanucchi; Giovanni Greco; Livia Macciò; Cristina Meneguzzi; Davide Mioni; Vincenzo Ostilio Palmieri; Michele Parisi; Doda Renzetti; Raffaella Rossin; Claudia Gandin; Luigi Carlo Bottaro; Mauro Bernardi; Giovanni Addolorato; Lisa Lungaro; Giorgio Zoli; Emanuele Scafato; Fabio Caputo
Journal:  Dig Dis Sci       Date:  2021-06-17       Impact factor: 3.487

Review 3.  Hepatic Encephalopathy-Related Hospitalizations in Cirrhosis: Transition of Care and Closing the Revolving Door.

Authors:  Catherine T Frenette; Cynthia Levy; Sammy Saab
Journal:  Dig Dis Sci       Date:  2021-06-24       Impact factor: 3.487

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.